Holen Sie sich die Stockscreener-App
7.15
0.00%
0.00
G 1 Therapeutics Inc Aktie (GTHX) Neueste Nachrichten
Acadian Asset Management LLC Boosts Stock Position in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
Insider Selling: Perry Andrew, G1 Therapeutics Inc [GTHX] Chief Commercial Officer divested 1,337 shares - Knox Daily
Recent Insider Activity Could Benefit G1 Therapeutics Inc (GTHX) - Knox Daily
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com India
GTHXG1 Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Pharmacosmos moves forward with G1 Therapeutics buyout - Investing.com
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period - StockTitan
Keeping an Eye on G1 Therapeutics Inc (GTHX) After Insider Trading Activity - Knox Daily
Panagora Asset Management Inc. Buys New Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
A company insider recently sold 1,337 shares of G1 Therapeutics Inc [GTHX]. Should You Sale? - Knox Daily
The Significance of Moving Averages in G1 Therapeutics Inc Inc. (GTHX) Price Performance - The InvestChronicle
G1 Therapeutics Inc (GTHX) gets rating Upgrade from JP Morgan - Knox Daily
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.12, a 0.28 Surge/Decline - The Dwinnex
It is Poised to be a Bull Market for G1 Therapeutics Inc (GTHX) - SETE News
G1 Therapeutics Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
It would be worthwhile to take a closer look at G1 Therapeutics Inc (GTHX) - US Post News
Stock Market Recap: G1 Therapeutics Inc (GTHX) Concludes at 7.09, a -0.28 Surge/Decline - The Dwinnex
The Potential Rise in the Price of G1 Therapeutics Inc (GTHX) following insiders activity - Knox Daily
A look into G1 Therapeutics Inc (GTHX)’s deeper side - SETE News
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose - Yahoo Finance
G1 Therapeutics, Inc. (NASDAQ:GTHX) Position Raised by Vanguard Group Inc. - MarketBeat
Vanguard Group Inc. Raises Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX) - Defense World
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP) - GlobeNewswire Inc.
GTHX stock soars to 52-week high, hits $7.1 amid growth - Investing.com
Pharmacosmos ventures into oncology and merges with G1 Therapeutics - MSN
TG Therapeutics Receives Clearance from FDA for Phase 1 Trial in Multiple Sclerosis for Allogeneic CAR-T Azer-Cel - CGTLive™
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates - MSN
G1 Therapeutics surges on merger deal with Pharmacosmos - MSN
Lowenstein Represents Crown Laboratories in Merger Agreement with Revance Therapeutics, Inc. - Lowenstein Sandler LLP
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Raised by Analyst - Defense World
Q3 2024 EPS Estimates for G1 Therapeutics, Inc. Lifted by Analyst (NASDAQ:GTHX) - MarketBeat
Pharmacosmos Group’s Acquisition of G1 Therapeutics - Global Legal Chronicle
G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Earn Q3 2025 Earnings of ($0.04) Per Share - Defense World
G1 Therapeutics (NASDAQ:GTHX) Issues Quarterly Earnings Results, Beats Estimates By $0.07 EPS - Defense World
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc.GTHX - Business Wire
Wedbush Equities Analysts Cut Earnings Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) - MarketBeat
G1 Therapeutics (NASDAQ:GTHX) Rating Reiterated by Needham & Company LLC - Defense World
HC Wainwright Lowers G1 Therapeutics (NASDAQ:GTHX) to Hold - Defense World
FY2027 Earnings Estimate for G1 Therapeutics, Inc. (NASDAQ:GTHX) Issued By Wedbush - Defense World
G1 Therapeutics (GTHX) Shares Surge Following Acquisition Announcement - The Fosters Leader
Pharmacosmos ventures into oncology and merges with G1 Therapeutics - Pharmaceutical Technology
G1 Therapeutics (NASDAQ:GTHX) Lowered to Hold at Wedbush - MarketBeat
Wall Street Analyst Upgrade G1 Therapeutics Inc [GTHX]. What else is Wall St. saying - The DBT News
FY2027 EPS Estimates for G1 Therapeutics, Inc. (NASDAQ:GTHX) Boosted by Wedbush - MarketBeat
G1 Therapeutics (NASDAQ:GTHX) Downgraded by Wedbush - Defense World
G1 Therapeutics Inc (GTHX) Q2 2024 Earnings: EPS of $(0.10) Beat - GuruFocus.com
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - ForexTV.com
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders - The Malaysian Reserve
G1 Therapeutics Sees Unusually Large Options Volume (NASDAQ:GTHX) - Defense World
Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos - MedCity News
3 Firms Steer $405M G1-Pharmacosmos Pharma Deal - Law360
Pharmacosmos Group to acquire G1 Therapeutics for $7.15 per share - TipRanks
Investors Purchase High Volume of Call Options on G1 Therapeutics (NASDAQ:GTHX) - MarketBeat
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher - Benzinga
Pharmacosmos to acquire G1 Therapeutics for $405 million By Investing.com - Investing.com Canada
Pharmacosmos Group To Acquire G1 Therapeutics - citybiz
Pharmacosmos to acquire G1 Therapeutics | Pharmaceutical | The Pharmaletter - The Pharma Letter
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders - Marketscreener.com
Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
G1 Therapeutics Acquisition and Executive Compensation Revamp - TipRanks
This trade activity should not be overlooked: G1 Therapeutics Inc (GTHX) - SETE News
Monitoring G1 Therapeutics Inc (GTHX) after recent insider movements - Knox Daily
Pharmacosmos to acquire G1 Therapeutics for $405 million - Investing.com
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today? - InvestorPlace
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders - Business Wire
1.25%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):